Loading asset research
Acurx Pharmaceuticals Inc. Common Stock
ACXPNasdaq · USD · StocksQuote as of · Exchange session not verified$1.40
0.00%
Today
ACXP
Loading 1D prices…
Market cap
$6M
Volume
64.5K
52w high
$8.3452w low
$1.31Company profile
Acurx Pharmaceuticals Inc. Common Stock
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Staten Island, NY, United States
Employees
4
Fiscal year end
1231
CIK
1736243
Session & valuation
Open$1.41
Previous close$1.40
Day high$1.41
Day low$1.38
30-day avg. volume160.5K
Outstanding shares5.3M
Diluted EPS-$5.32
Latest annual period
P/E (trailing)-0.26
P/E (forward)-0.80
Price / book0.80
Beta-2.02
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| KAPAKairos Pharma Ltd. Common Stock | $6M | $0.00 | — | -$0.30 | +4.64% | Buy |
| DRMADermata Therapeutics Inc. Common Stock | $5.9M | $0.00 | — | -$8.16 | -0.83% | Buy |
| PCSAProcessa Pharmaceuticals Inc. Common Stock | $5.8M | $0.00 | — | -$10.36 | +12.43% | Buy |
| XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares | $6.3M | $0.00 | — | -$0.80 | +1.59% | Unrated |
| ENVBEnveric Biosciences Inc. Common Stock | $6.4M | $0.00 | — | -$36.24 | -1.37% | Unrated |